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ABSTRACT Alzheimer’s disease is themost common cause of dementia and is widely believed to be due to the accumulation of
b-amyloid peptides (Ab) and their interaction with the cell membrane. Abs are hydrophobic peptides derived from the amyloid
precursor proteins byproteolytic cleavage.After cleavage, thesepeptidesare involved in a self-assembly-triggered conformational
change. They are transformed into structures that bind to the cell membrane, causing cellular degeneration. However, it is not clear
how these peptide assemblages disrupt the structural and functional integrity of the membrane. Membrane ﬂuidity is one of the
important parameters involved in pathophysiologyof disease-affected cells. Probing theAbaggregate-lipid interactionswill help us
understand these processes with structural detail. Here we show that a ﬂuid lipid monolayer develop immobile domains upon
interactionwithAbaggregates. Atomic forcemicroscopyand transmission electronmicroscopydata indicate that peptide ﬁbrils are
fragmented into smaller nano-assemblages when interacting with the membrane lipids. Our ﬁndings could initiate reappraisal of
the interactions between lipid assemblages and Ab aggregates involved in Alzheimer’s disease.
INTRODUCTION
The excessive generation and accumulation of the Ab peptide,
a peptide 40–42 amino-acids long, in the vulnerable brain
regions of patients with Alzheimer’s disease (AD), is be-
lieved to be the major cause for the disease. Human Ab
peptide is expressed intracellularly, however, if the peptide
concentration is too high, the peptides aggregate, and are
further secreted out of the cell. These peptides are produced
by a proteolytic processing of large APPs by an aspartyl
protease (BACE-1) and a multiprotein complex mainly con-
sisting of g-secretase (1). Ab is expressed in both soluble
and assembled forms, and is observed in many cellular com-
partments, such as the endoplasmic reticulum, the Golgi, the
Golgi intermediate compartment, and the trans-Golgi network
(2). The BACE-1 cleavage is believed to occur in the
trans-Golgi and endocytic compartments, and the g-secretase
cleavage is mediated by the activity of presenilins normally
localized to the endoplasmic reticulum and pre-Golgi com-
partments.
Though the assemblage kinetics of the Ab aggregates is
well known, exactly how this diverse molecular species,
residing in multiple subcellular sites, elicits cellular toxicity
is not well understood. There are a number of different points
of view as to the toxicity of Ab. Early work has shown that
Ab accumulation in APP mutant neurons inhibits the ac-
tivities of the proteasome (3). Amyloid peptide toxicity may
be due to its interaction with metals such as copper, and
proteins like acetylcholinesterase (4). Neuronal signaling is
affected by amyloid peptide interaction with transducers of
the Wnt/b-catenin signaling pathway, including b-catenin
and glycogen synthase kinase 3b resulting in toxicity (4).
There are several membrane binding proteins known to be
associated with amyloid-triggered toxicity (5). Others
believe it to be either pore formation or the formation of
nanoaggregates that is responsible for disrupting membrane
functions (6–9). Although this is the interest of this study, as
we see signiﬁcant lipid association with amyloid peptides
and associated changes in the lipid and amyloid organiza-
tion, it should be noted that the amyloid toxicity is not
exclusively correlated to the lipid binding alone. As mem-
brane lipids are intimately associated with these peptides in
both soluble and assembled form, it is crucial to know how
the different assemblage states of the peptides affect mem-
brane dynamics and functionality. This is particularly im-
portant as there is compelling evidence indicating that the
toxicity of these aggregates lies in the soluble oligomers and
not with the matured ﬁbrils (polymers) (10), since for the
same number of monomers we have many more soluble
oligomers than ﬁbrils. It is not known whether the toxicity is
due to the size of the soluble oligomers or to the number of
them present in the cells, but the interaction of the membrane
lipids with the peptides, as well as the change in aggregate
size, is important. These structurally transformed aggregates
are immobile and known to interact with cells in their im-
mediate proximity (11,12). While these processes are well
established, there are some pertinent questions that remain
unanswered.
What is the relationship between the ﬁbrils and soluble
oligomers with respect to membrane malfunction? How
stable are the ﬁbrils when in contact with the cell membrane?
Is it possible to decompose the toxic nano-aggregates into
smaller, nontoxic aggregates in the membrane micro envi-
ronments or vice versa? There is a growing consensus sug-
gesting that amyloidogenic processing occurs in domains
in the membrane enriched with secretases BACE-1 and
g-secretase. Recent efforts in the quest for a vaccine for AD
suggest that the matured Ab ﬁbrils produced by BACE-1 and
g-secretase are dynamic entities that can be broken down by
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antibodies in transgenic animals and AD patients’ brains
(13). However it should not be ruled out that this could be
due to a mass action of the antibodies, or via stimulation of
cellular clearance mechanisms (14). Grimm et al. (15) re-
cently proposed that Ab1–42 promotes breakdown of the lipid
sphingomyelin as part of its physiological function, whereas
Ab1–40 reduces the cholesterol production. Hence un-
derstanding the Ab ﬁbril assemblage modulation could be
very important to discern these vital processes. Neuronal
cells are highly sensitive to microrheological changes be-
cause of their highly polarized morphology and large number
of specialized microdomains.
In this study we have investigated the interaction of ﬁbrils
and soluble oligomers with cell membrane model systems.
Previous studies with model monolayers have demonstrated
that mixtures of lipids mimicking the composition of the
outer leaﬂet of plasma membranes exhibit a similar kind
of domain structure and stability to that of live cells (16).
However, even though these studies were performed using a
lipid mixture, they still do not represent the native condition
of cells. This is because of the lack of actin, cytoskeleton,
membrane proteins, and the inner lipid leaﬂet. Actin alone
has been shown to act as a barrier that hinders the diffusion
of membrane lipids (17–19). Even in regard to this, the lipid
monolayer is a good model system for studying the inter-
actions between lipids and peptides. This system was used
in the single-particle tracking (SPT) experiments and the
atomic force microscopy (AFM) experiments as well as in
part of the transmission electron microscopy (TEM) study.
Another model system for the cell membrane is represented
by giant vesicles. These vesicles have a diameter;1–10 mm
and the interior of these vesicles consists of freely moving
smaller nested vesicles. This is a minimal system with great
relevance to membrane protein interactions where both in-
tervesicular transport as well as lipid-peptide interactions can
be visualized. The giant-unilamellar vesicle (GUV) system
was used in the ﬂuorescence resonance energy transfer (FRET)
experiments as well as in part of the transmission electron
microscopy (TEM) study. This system is far from the cellular
bilayer where the lipids are distributed asymmetrically over
the inner and outer leaﬂets. Both exofacial and cytofacial
leaﬂets of the cell membrane bilayer are different in lipid
composition and microﬂuidity. Furthermore, our experimen-
tal condition does not provide the micro environment of
the cytoskeleton interior that is present in vivo (20). These
caveats are kept in mind when interpreting the current data.
Despite all these shortcomings, this system is easy to rep-
licate in vivo with different membrane components. Specif-
ically it is easy to add amyloid peptide in different aggregates
and study their interaction. Using these model systems we
observe that the amyloid aggregates have an afﬁnity for the
lipid bilayer in giant vesicles. In lipid monolayers we ob-
serve drastic interfacial rheological changes associated with
peptide aggregate binding. We also observe fragmentation of
matured ﬁbrils, as well as fragmentation of the protoﬁbrils,
on association with lipids in our model systems. In this work,
we show that Ab peptide, whatever the form of aggregate,
might be involved in the generation of immobile micro
domains which will have drastic cellular implications par-
ticularly in neuronal cells.
MATERIALS AND METHODS
Lipids
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG); 1,2-dioleoyl-
sn-glycero-3-phosphate (DOPA); 1,2-dioleoyl-sn-glycero-3-f[N (-5-amino-
1-carboxypentyl)imino-di-acetic acid] succinylg (Nickel Salt); and egg yolk
phosphatidylcholine were obtained from Avanti Polar Lipids (Birmingham,
AL). 1,2-Dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylam-
monium salt, and Texas Red (TR) was obtained from Molecular Probes
(Eugene, OR). All lipids were used without further puriﬁcation.
Peptides
Ab1–42 and Ab1–40 were prepared by Fmoc-solid phase peptide synthesized
in W.M. Keck Facility at Yale University (New Haven, CT). The peptides
were puriﬁed using RP-HPLC, analyzed by matrix-assisted laser desorption
ionization time of ﬂight mass spectrometry and lyophilized at the PAN
facility Stanford University. FITC-Ab1–42 and Ab42–1 were obtained from
AnaSpec (San Jose, CA).
Ab peptide preparation
The Ab1–40 and Ab1–42 were suspended in 90:10% hexaﬂuoroisopropanol/
triﬂuoroacetic acid for pretreatment. After complete dissolution, the solvent
was removed using dry Argon gas. The remaining ﬁlm was placed in a
vacuum chamber. The ﬁlm was redissolved in a 1 mM NaOH solution, and
the pH was adjusted to 7.4 using a 20 mM NaOH solution to obtain Ab
peptide in monomeric form. This solution was aliquoted and lyophilized
again. The lyophilized powder was dissolved in phosphate-buffered saline
(PBS) at pH ¼ 7.4 and 155 mM NaCl to a working concentration of 200
mM. To prepare the soluble oligomer fractions of the peptides, the Ab1–42
sample was placed at 4C for 24 h and the Ab1–40 was incubated for 72 h at
room temperature. Mature ﬁbrils were prepared by incubating the lyoph-
ilized peptide dissolved in PBS along with 5% preformed seed at 37C for
15–30 days. The monomers were thereafter separated from the ﬁbrils by
centrifuging the sample at 5000 rpm for 10 min, thereby pelleting the
matured ﬁbril, leaving the monomer in the supernatant which is removed.
When used, the working concentration of the peptides was 200 nM.
Miniature Langmuir trough
In studying the Ab-lipid monolayer interactions, a need arose for a miniature
Langmuir trough. The reasons include reactant amounts and a need to
improve single particle tracking (SPT) measurements. There have been a
few attempts at making miniature Langmuir troughs, the goal usually being
aimed at improving diffusion measurements at the air-water interface and
reducing contamination. Lipid monolayer tracking experiments at the air-
water interface have inherent problems not found in supported bilayer ex-
periments, due to the inﬂuence of air currents and convective ﬂows in the
subphase. There are a few different approaches to address these problems;
one uses a circular ring residing in the subphase right below the interface in a
Langmuir trough, which acts as a barrier to subphase ﬂow (21). Another
group (22) encapsulated their setup under glass and reduced the trough size
to suppress air ﬂow and reduce contamination. The resulting trough was
small and light, allowing it to ﬁt on a microscope stage. Our approach is
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along the same lines, reducing the size; the ‘‘trough’’ that we constructed
consists of a sessile drop sitting on a polydimethylsiloxane stage with an
inlet and an outlet (Fig. 1). Surrounding the sessile drop are glass sides to
reduce air ﬂow, evaporation, and contamination; however, the setup is not
entirely enclosed. The setup contains three droplet stages, to facilitate
multiple experiments at the same time. The area per molecule is adjusted by
either injecting more subphase liquid into the interior of the drop or by
removing some of the subphase. Reduced subphase volume is of importance
when, in our case using hybridized oligonucleotides as linkers between
monolayer lipids and ﬂuorescently tagged subphase vesicles as probes, this
system is described in Single Particle Tracking (SPT). A reduced subphase
volume allows for shorter hybridization time and smaller amounts of
analyte. This setup has a subphase volume of ;40 mL, which is approx-
imately two orders-of-magnitude less than the subphase of a conventional
Langmuir trough.With this setup we see a great reduction in convective ﬂow
and also a much shorter experiment turnover time. Formation of a drop is
accomplished by injecting subphase liquid through the inlet channel; the size
of the drop can be further adjusted by either injecting more liquid through
the inlet or by aspirating the subphase through the outlet channel. A
monolayer can then be spread on top of the drop; all lipid monolayers are
spread using a chloroform solution to ensure quick solvent evaporation and
immiscibility, depositing the lipids at the interface only. The Ab peptides in
PBS solution are introduced through the inlet channel, and simultaneously,
the same amount of subphase is withdrawn using the outlet, so that the
volume of the drop is maintained constant. To remove excess peptides or
other material that has been introduced into the system, clean subphase
liquid can be injected at the same time as the subphase with excess material
is aspirated. The drawback with this smaller trough is that there are some
problems when air bubbles form and rise to the interface; the experiment
then needs to be aborted, and we do not yet have a way of measuring the
surface pressure. The miniature Langmuir trough was used for the SPT,
AFM, and part of the TEM experiments.
Atomic force microscopy (AFM)
AFM analysis was performed using a Digital Instruments Multimode
NanoScope IIIa SPM (Veeco Metrology Group, Santa Barbara, CA). Silicon
AFM tips (model PPP-NCH) for tapping mode were purchased from
Molecular Imaging (Tempe, AZ) and was used for imaging the sample at a
rate of 0.5–2 Hz depending on the scan size. AFM is widely used to
investigate the aggregate structure of amyloid-forming peptides (23–26).
The samples to be investigated were prepared using the micro Langmuir
trough. Experiments were conducted using pairs of drops; both drops’
subphase consisted of 40 mL PBS, one drop having a lipid monolayer, the
other one not. The monolayer, which consisted of POPG and DOPA lipids,
was spread on the surface of the drop. Two microliters of Ab1–40 is then
injected into the interior of the drop. Once introduced, the peptide quickly
absorbed to the drop-air, drop-lipid interface. The drop-air interface is the
control system, allowing us to know what the peptide looks like before
interacting with the monolayer lipids. The monolayers were thereafter
transferred to a silicon wafer using a Langmuir-Schaffer horizontal transfer
technique where the wafer was brought into contact with the drop interface.
Once the monolayer had been transferred, the wafer was carefully washed in
Millipore water to remove salts from the buffer solution that would
otherwise interfere with the imaging. The ﬁlms were then investigated by
AFM to gain information on their structural features at the submicrometer
level.
Single particle tracking (SPT)
To deduce the interfacial rheological properties of the monolayers and the
effect of the Ab peptides, SPT was implemented (27,28). Similarly to AFM
experiments already described, experiments were conducted using pairs of
drops, but this time, the reference system was that of a lipid monolayer alone
(POPG/DOPA) spread at the air-water interface, and the other system was
that of a lipid monolayer, spread ﬁrst, after which peptide aggregates were
introduced into the interior of the drop. Tracking of the lipids was facili-
tated using a technique developed by Yoshina-Ishii and Boxer (29). This
technique allows for ‘‘smart tethering’’ of ﬂuorescently labeled vesicles to
lipids in a monolayer or bilayer. The smart linker is a modiﬁed lipid, where a
oligomer 16-bases-long is attached covalently to the lipid headgroup. Using
this type of linker you can select for the vesicle that has the complementary
lipid attached to it. In this study we labeled egg-yolk phosphatidylcholine
vesicles with 1.5% Texas Red (TR) lipids. Enough DNA-lipids were added
to allow for a maximum of one DNA-lipid per vesicle. This way we reduce
the likelihood of getting more than one tether per vesicle. However, if we
have perfect insertion of the DNA-lipid into the vesicle, we probably have a
number of vesicles that do not have the DNA-lipid in it, so they will not
attach to the monolayer and can be ﬂushed away. A monolayer with
1:10,000 DNA-lipids is spread on top of the drop on the ‘‘trough’’, and once
the chloroform from the spreading solution evaporated, TR-labeled vesicles
with the complimentary lipids are injected into the subphase using the
injection channel in the stage. Once the complimentary oligonucleotides in
the TR-labeled vesicles have hybridized with the DNA-lipids in the mono-
layer, these vesicles are constrained to the two-dimensional air-water inter-
face. After hybridization, the subphase is ﬂushed with clean buffer to remove
any excess ﬂuorescent vesicles not attached to the monolayer. If Ab
aggregates are used in the system, these are injected into the subphase after
the monolayer is spread, but before the injection of the ﬂuorescent vesicles.
After incubation for 10 min, the subphase is ﬂushed to remove any peptide
not yet interacting with the monolayer to avoid interactions between the
peptide and the vesicles. A Nikon Microphot-SA ﬂuorescence microscope
(Nikon, Marunouchi, Tokyo) equipped with a Princeton Instruments
PentaMAX intensiﬁed CCD camera (Princeton Instruments, Trenton, NJ)
was used to image the SPT experiments. Images were captured at a rate of 11
frames per second and analyzed using Metamorph v.6.3 from Molecular
Devices (Downingtown, PA). Further analysis was conducted using
Microsoft Excel (Microsoft, Redmond, WA).
FIGURE 1 Novel micro Langmuir trough. With a subphase volume of
;40 mL, this ‘‘trough’’ is much smaller than a conventional Langmuir
trough. The area per molecule can be varied by adjusting the volume of the
drop. The monolayer is spread on top of the drop. Peptides and vesicles are
injected into the interior through the inlet. As peptides and vesicles are
injected, subphase ﬂuid is removed at the same rate through the outlet
channel, such that constant volume is maintained. The radius of the drop is
;3 mm. We do not yet have a functional way for this system to control the
surface pressure if we want to have a ability to inject substances into the
subphase.
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Confocal microscopy, FRET, and giant
vesicle preparation
Confocal microscopy
The membrane-Ab peptide interaction in giant vesicles was studied using
confocal microscopy utilizing the ﬂuorescence resonance energy transfer
(FRET) technique. To facilitate these studies, a ﬁve-well sample viewer was
prepared for viewing the samples. Using a diamond-tipped drill, 10 holes
were drilled in a microscopy slide. Six strips of double-sided tape were used
to form ﬁve channels, each channel with a hole at both ends. A coverslip
functionalized with a His-tag protein was then attached, using double-sided
tape and epoxy glue to form ﬁve enclosed channels, each with an inlet and an
outlet. The His-tag protein allowed us to ﬁx the vesicles to the coverslip. The
sample is viewed through the No. 1.5 coverslip, covering the channels. An
inverted confocal microscope, Leica SP2 AOBS, was used to capture the
images (Leica, Wetzlar, Germany). The excitation wavelengths were 488 nm
(FITC-Ab) and 543 nm (TR).
Giant vesicle preparation
Phospholipid stock solutions were dissolved in chloroform to yield a con-
centration of 0.2 mg/ml. Giant unilamellar vesicles (GUVs) with POPG,
DOPA, Ni lipids, and TR-lipids (1:1:0.02:0.01 molar ratio) were prepared
using the rotary evaporation method (30). Aliquots of giant vesicles
suspended in PBS at pH ¼ 7.4 were used in the FRET experiments.
Fluorescence resonance energy transfer (FRET)
Fluorescence resonance energy transfer (FRET) is a robust and sensitive
technique widely used to study the distance between two different ﬂuoro-
phores and is only possiblewhen twoﬂuorophores are in close proximity (31).
This technique has been used for similar systems where the interactions
between peptides and membrane lipids have been studied (32,33). To ac-
complish FRET, a donor ﬂuorophore is excited by an incoming photon. If an
acceptor ﬂuorophore is in close proximity, the acquired energy can be
transferred nonradiatively between the ﬂuorophores, and a photon of lower
energy is emitted from the acceptor ﬂuorophore. The efﬁciency of FRET is
dependent on the inverse sixth power of the distance between the molecules,
making this a very useful method for visualizing and studying the in-
corporation of peptides into a bilayer. Other techniques for studying the
incorporation of the peptide into bilayers could be accomplished by in-
cubating the peptide with vesicles followed by centrifugation and spectro-
scopic analysis. Themajor disadvantagewith that technique is that it is harder
to separate larger aggregates from the vesicles, and also requires two
steps—whereas the FRET technique used here is a one-step technique in
which incorporation is easily seen visually. The increase in FRET intensity of
the acceptor or reduction of the donor ﬂuorescence intensity gives a direct
measure of proximity information between the donor-acceptor carrying
moieties.
Transmission electron microscopy (TEM)
Transmission electron microscopy (TEM) was facilitated using a JEOL 1230
electron microscope (JEOL, Peabody, MA) at the Cell Sciences Imaging
Facility at Stanford University. All the TEM work was conducted with the
subphase consisting of PBS. A drop of PBS is formed on the same sample
stage described earlier; the Ab peptide aggregate is injected into the interior
of the drop. If a lipid monolayer is desired for the experiment, this is spread
before injection of the peptide. The system is allowed to equilibrate for
15 min; at that time a TEM grid is brought to the air-water interface and the
aggregates are transferred horizontally. After the peptides have been ﬁxed to
the grid, the uranyl acetate (UA) stain is applied with a drop of 2% UA
solution on the back side of the grid. The drop is allowed to engulf the grid
and after 5 min, the grid is washed three times by immersion in a rinse made
of the same solution, but without the UA. Since the peptides and lipids are
already ﬁxed to the surface when the stain is applied, there should be
minimal effect of the stain on the peptide structures.
RESULTS AND DISCUSSION
FRET
To study the membrane-Ab peptide interaction, TR-lipids
were incorporated in the bilayer of giant vesicles and the Ab
peptide was labeled with FITC. Ten microliters of GUVs in
PBS buffer were injected into the sample holder described
earlier. The vesicles were allowed to attach and were imaged
in the absence of peptides (data not shown). FITC-Ab1–42
soluble oligomer/ﬁbrillar mixture was introduced into the
sample chamber and imaged. Fig. 2, A–D, is a confocal ﬂuo-
rescence image of a giant vesicle using different excitation
and emission wavelengths. Fig. 2 A depicts the vesicle ex-
citing and imaging the TR-lipids. Fig. 2 B depicts the FRET
after peptide has been added to the system. Signiﬁcant FRET
is observed, which implies that FITC-Ab is localized in close
proximity with the membrane TR-lipids. Imaging the FITC
channel after peptide addition (Fig. 2 C), a weak ﬂuores-
cence is observed everywhere except for where the vesicle
is located, where very little or no ﬂuorescence at all is
observed—indicating energy transfer between the FITC-
labeled bound peptide and the TR lipids in the membrane.
The reduction in ﬂuorescence seen in Fig. 2 C can, in ad-
dition to the FRET, be attributed to the metal quenching by
FIGURE 2 Giant vesicles in confocal microscope. Scale bar represents
1 mm. (A) Exciting Texas Red directly; imaging Texas Red emission. (B)
The same vesicle under FRET, exciting FITC and imaging Texas Red, we
see a weaker signal than direct excitation, as expected. (C): Exciting the
FITC-labeled peptide reveals energy transfer to the TR-labeled membrane
lipid as there is no increase in FITC signal along the GUV perimeter. (D)
FRET of nested vesicle moving inside giant vesicle, suggesting that peptides
can pass through the vesicle membrane.
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the Ni-lipids in the vesicles (34). However, FRET can be
seen in Fig. 2 B, which would not be seen if all the quenching
seen in Fig. 2 C would be attributed to the Ni-lipids. This
quenching should be seen in all imaged channels, not just in
the FITC channel; therefore, we attribute the quenching seen
in Fig. 2 C partly to FRET.
The Fo¨rster radius for the FITC/TR donor-acceptor pair is
R0–50 A˚ (35). Hence, the observation of FRET reveals that
the peptide aggregate must reside within 100 A˚ of the
membrane TR lipid. The incorporation of the peptide in the
bilayer was near-complete during the time of our sample
preparation (5 min). This indicates that the binding of Ab
aggregates to the membrane is essentially instantaneous, since
we see no increase in FRET with time. Green ﬂuorescent
protein was used as a control to check the ﬂuorescence signal
bleed in the instrument. The FRET intensity for the same
amount of the protein added was minimal (data not shown),
indicating the observed FRET is consistent with the mem-
brane Ab peptide interaction. The Ab aggregates can move
through the giant vesicle membrane to its interior; this ob-
servation was made through the visible FRET in small ves-
icles nested inside the giant vesicles. Brownian motion of the
nested vesicles was observed, suggesting that they are not
invaginations of the bigger vesicles, but freely moving
entities (Fig. 2 D). These vesicles are seen inside the GUVs
before the peptide is added, so the vesicles are not
invaginated because of the peptide. The peptide is transferred
to the internal vesicles since FRET is seen in these nested
vesicles, indicating that Ab can rapidly cross the giant ves-
icle bilayer and incorporates with the bilayer of nested ves-
icles. The mechanism for this transfer is not known, but we
speculate that the peptide that is incorporated into the outer
membrane is transferred as the nested vesicles collide with
the encapsulating membrane. If pore formation is the mech-
anism that rules this system, then pores could be formed and
the peptides transfer through the pores; however, we have
seen no evidence for pore formation in our system. No
experiments were conducted on unlabeled Ab, so it is not
known if this membrane penetration is due to the FITC label.
We see the same results for both Ab1–40 and Ab1–42. It
should be mentioned that passage of the soluble oligomers
through the membrane is noteworthy, as these species are
implicated in the neuronal toxicity (36). The soluble
oligomers of Ab (37,38), IAAP (39), and a-synuclein (40)
have previously been shown to be localized to the cell
membrane, inducing membrane leakage and, as a result, an
ion imbalance. To the best of our knowledge, this is the ﬁrst
time that it has been shown that a mixture of matured ﬁbrils
and protoﬁbrils has generated more soluble oligomers (an
activity mediated by giant vesicles). This observation has
biological implications because it has been shown that
introducing the peptides to the cell either by microinjections
of Ab1–42 or by a cDNA-expressing cytosolic-Ab1–42
rapidly induces cell death of primary human neurons, both
in ﬁbrillar and nonﬁbrillar forms. Concentrations as low as
1 pM or 1500 molecules/cell are known to be neurotoxic
(41). The present results show that assembled Ab prepara-
tions have an ability to form toxic nanoaggregates when in
contact with membrane lipids. A closer look at the GUV
suggests that the ﬂuorescence is granular, not uniform. This
indicates that the peptides binding to the membrane result in
a surface excess, which appears as granular aggregates. This
may be due to the peptides binding to the membrane and
changing the lipid domains from ordered liquid crystalline
lipid domains to partially ordered domains. Consequently
this leads to a curvature imbalance of the vesicular mem-
brane (42). Further, the defects will also lead to diffusion of
the soluble oligomers into the membrane, a mechanism that
has previously been observed in the case of a-synuclein
membrane interactions (43).
Aggregate structures as observed by AFM
To further explore the nature of Ab1–40 aggregates in the
membrane environment, Ab1–40 assemblages were incorpo-
rated into lipid monolayers and studied using AFM. The
lipids used in this system have a negative charge, making
them more representative of the inner leaﬂet of the cell,
where the peptides are formed. Fig. 3 A depicts an AFM
image of a DOPA/POPG (1:1) monolayer without the pep-
tide. The lipid monolayer alone forms a smooth ﬁlm, with
wavelike features that are attributed to the separation of the
lipids into smaller domains when the system is dehydrating.
The lighter regions in the height mode AFM images rep-
resent higher topography. In systems with lipids, the darker
regions are assigned to the monolayer absorbed to the silicon
wafer, and in the systems without lipids, the darker regions
are assigned to the silicon wafer itself (23,24). Injecting the
soluble oligomers alone and letting them absorb to the air-
water interface results in polydisperse ﬂat discoid aggregates
(Fig. 3 B), these objects not only have a height difference (3–
25 nm taller than the silicon wafer), but also a difference in
viscoelastic response, which is apparent in the phase mode
image (data not shown). The soluble oligomers adsorbed at
the air-water interface form domains that are between 3- and
25-nm high, which is higher than the ﬁbrils or the soluble
oligomers of Ab1–42 on graphite or mica substrates (25). This
suggests that the air-water interface induces lateral aggrega-
tion of the Ab1–40 peptides on the water surface. These
domains are ﬂat, with a maximum height of 21 A˚. Solid-state
NMR studies suggest a parallel b-helical arrangement, where
two adjacent strands of Ab1–42 pack with a Ca-Ca distance
of 4.86 0.5 A˚ (44). The smallest observed peptide peaks are
high enough to accommodate four units of Ab1–40 peptide
monomers, indicating that soluble oligomers consist of Ab1–40,
arranged one above the other. A lateral assembly of several
units will result in a discoid of 25 nm in diameter as observed
in the AFM (25). Previous studies indicate that monolayers
can condense upon transfer to a solid support and form solid
phase islands consisting of lateral aggregates (45). A striking
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difference in aggregate distribution is observed when the
peptides are injected into a drop with a lipid monolayer at
the air-water interface (Fig. 3 C). When the introduced
peptide aggregates incorporate into the lipid monolayer, the
average diameter of the disklike soluble oligomers is reduced
from 25 nm to 16 nm. The lipids further reduces the aver-
age height of the aggregates from 13.3 A˚ to 9.5 A˚. Fig. 3 D
displays the change in aggregate size in the two different
systems. We see a reduction in aggregate size and also a
change in the size distribution. The peptide at the air-water
interface is fairly polydisperse, whereas, when the same
system has interacted with lipids, the size distribution is
much narrower. This indicates that the lipids induce frag-
mentation of the peptide assemblages. An aggregate height
of ;13.3 A˚ would represent a trimeric or dimeric peptide
aggregate, whereas a height of 9.5 A˚ would represent a dimer.
We ﬁnd a reduction in aggregate number from three to two
soluble oligomer units. Our AFM data suggest that the soluble
oligomers at the air-water interface, or soluble oligomers in-
corporated in a lipid monolayer, accommodate smaller pep-
tide units compared to the ﬁndings of previous studies (25,
46). This could be due to our method of preparation of the
sample.
TEM analysis visualizing the Ab
aggregate-lipid interaction
The results so far presented suggest that lipophilic Ab
aggregates interact with the cellular lipid membrane leading
to structural changes of the aggregates. We used TEM to
image matured ﬁbrils and soluble oligomers of the Ab1–40
and Ab1–42 peptides incorporated in lipid monolayers and
bilayers of GUVs. We used both systems and will hereafter
in this section refer to the peptides as Ab. We investigated
whether these aggregates sever the cell membrane integrity
upon incorporation. Previous studies of incorporation of Ab
peptides in lipid membranes, utilizing AFM to investigate
vesicles, suggested such possibilities (39,47). Fig. 4 A is a
TEM image of the soluble oligomeric fraction of the Ab
peptide at the air-water interface. The image shows small
aggregates with a diameter of;6–8 nm. However, when the
same fraction is introduced into a drop with a lipid mono-
layer at the air-water interface, the soluble oligomers of Ab
are almost nonexistent in the TEM images. We presume that
the soluble oligomers are divided into smaller fragments as
seen with the AFM, and that these aggregates are of such a
small dimension that their contrast is too low to be visible
(Fig. 4 B). Matured Ab ﬁbrils absorbed to the air-water
interface and incubated for 1 h appear as a ﬁbrous mesh (Fig.
4 C), with the individual ﬁbers having a diameter of;6–8 nm
and variable length. When these ﬁbrils are incubated in a
drop covered by a lipid monolayer for 1 h, they fragment.
The fragments appear as a pattern of globular structures of
soluble oligomers of;3–4 nm in diameter. Fig. 4 D shows a
fragmentation pattern with generation of globular, short
FIGURE 4 TEM images of soluble oligomers and ﬁbrils Ab1–40. The
scale bar represents 100 nm. (A) Soluble oligomers at the air-water interface.
(B) Soluble oligomers in a lipid monolayer, structures are too small to see,
but the stain is visible, indicating peptide presence. (C) Fibrils at the air-
water interface, large three-dimensional networks are present. (D) With a
lipid monolayer present, the mature ﬁbrils are broken down into soluble
oligomeric components.
FIGURE 3 AFM height mode images. (A) Lipid monolayer 0.5 mm 3
0.5 mm 10-nm height scale reveals very small height undulations, indicating
a fairly uniform monolayer. (B) Ab1–40 without lipid monolayer reveals
many high peaks. (C) Introducing the peptides into a lipid monolayer reduces
the peak height and also peak width, in comparison to the system in panel B.
(D) Aggregate size and size distribution, peptide with lipids, and peptide
alone, the system with lipids induce a breakup of larger aggregates.
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ﬁbrils of 25–75 nm in length. This indicates that matured Ab
ﬁbrils can generate soluble oligomers in the presence of
lipids. In connection with this observation, it is worth men-
tioning that there is evidence suggesting that, in speciﬁc
micro environments such as inﬂammatory conditions, the
ﬁbrils also elicit toxicity like that of soluble oligomers (48).
In the light of the present discoveries, this could be due to the
generation of smaller aggregates from the matured ﬁbrils
upon interaction with lipids. We propose that when ﬁbrils are
in contact with the lipid domains, it is not necessary that the
whole ﬁbril is in contact with the membrane lipids. Instead,
we suggest that since different parts of long ﬁbrils can be in
contact with membrane domains, they can be in contact with
different subdomains. A ﬁbril that is ﬁrmly anchored into
different subdomains, which might be moving independently
in different directions, is slowly teased apart (Fig. 5). The
disruption of ﬁbrillar structures into oligomeric structures
has also been observed in tubulin-lipid complexes (49). Our
observation is also consistent with the previous work of
Tashima et al. (50), who reported that there was no ﬁbril
formation in the liposomal preparation without cholesterol.
The Ab aggregates’ effect on giant vesicles is indicative of
amyloid dissolution in the vesicle membrane. The incorpo-
ration of aggregates into the membrane leads to both ordered
and disordered domains in the membrane. The disordered
domains appear as dark regions in the TEM images, where
more of the UA molecules have been incorporated. The UA
incorporates in and around the peptide aggregates, which are
more prevalent in the disordered domains (Fig. 6 A). An
image at higher magniﬁcation of the ordered and disordered
regions is shown in Fig. 6 B. The total conversion of mature
ﬁbrils to soluble oligomers is visible in Fig. 6 C. Examina-
tion of the lipid membrane at a higher magniﬁcation (Fig.
6 D) reveals that the peptide aggregates are globular and
localized to the disordered domains, adjacent to the ordered
areas of the membrane. The Triton-X micelle is also known
to produce such disordered domains when interacting with
the lipids in the membrane (51). This induced disorder is in
turn compensated by the formation of larger-ordered do-
mains as well. The soluble oligomeric forms of several
amyloid assemblages are known to dramatically increase
the ionic permeability of planar lipid bilayers. Micropipette
aspiration studies indicate that the Ab aggregates induce a
strong membrane destabilization and leakage of the entrap-
ped solutes in GUVs (38). Studies of the Ab peptide in-
teraction with plasma, endosomal, and lysosomal membrane
compartments in the brain of an AD patient have indicated a
decrease in ﬂuidity of the membrane (52,53). This corrob-
orates with our ﬁndings in the monolayer studies, where
peptide incorporation reduces total diffusion in the system.
Peptide inﬂuence on monolayer ﬂuidity
To investigate the inﬂuence of Ab1–40 aggregates on the lipid
membrane ﬂuidity, Ab1–40 soluble oligomers were incorpo-
rated into lipid monolayers and studied using SPT. The lipid
monolayer alone is ﬂuid, with no solid domains (54). The
‘‘micro trough’’ was developed for these experiments and a
great reduction in convective ﬂow was seen, compared to
conventional Langmuir troughs. However, some ﬂow still
exists and will have to be taken into account. The motion of
the vesicles can be divided up into a convective part and a
Brownian motion part. Subtracting the average displacement
from the total displacement of each vesicle leaves random
FIGURE 5 Proposed model for the fractionation of Ab ﬁbrils. The ﬁbril
consists of soluble oligomeric substructures; these come together to form a
ﬁbril because of hydrophobic interactions. The hydrophobic peptide
segments preferentially incorporate into the hydrophobic tails of the
monolayer lipids. Micro domains in the monolayer moving in different
directions can tease the ﬁbril apart, decomposing it into smaller fragments.
FIGURE 6 Giant vesicles with Ab1–40 peptide incorporation. The scale
bar represents 100 nm. The uranyl acetate incorporates in and around the
peptide aggregates. (A) Protoﬁbrillar peptide aggregates are more incorpo-
rated in the disordered domain, the disordered domain being outside the
GUVs. (B) Higher magniﬁcation image, revealing ordered and disordered
regions, arrows pointing out the peptide in the disordered regions. (C) The
total conversion of mature ﬁbrils to soluble oligomers is visible; soluble
oligomers can be seen, but no ﬁbrils. The interior of the GUVs have less
visible oligomers than the surroundings, but is darker, indicating more of the
smaller peptides in those regions. (D) Looking at the lipid membrane at a
higher magniﬁcation reveals that the peptide aggregates are globular,
localized to the disordered domains, whereas where the ordered domains are,
no oligomers can be seen.
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movement (see Eq. 1). This scheme allows for tracking of
individual vesicles, and based on their positions in each
image and the time-lapse between each image, we can cal-
culate the diffusion coefﬁcient for the lipids. This position is
analyzed using the SPT plug-in of the Metamorph software.
The output from the program is particle-coordinates in each
image frame and the elapsed time from the ﬁrst image:
Æ4Dtæ ¼ Æx2æ Æxæ2: (1)
Using this relationship, where x is the direction vector, the
random walk diffusion can be calculated and the diffusivity,
D, can be calculated. In the system without peptide, there are
no apparent domains, where the vesicle trajectories display a
random walk (Fig. 7 A). The diffusion coefﬁcient for the
plain POPG/DOPA monolayer is 0.2 mm2/s (Fig. 7 B). When
peptides are introduced, solid domains appear, and in these
regions the vesicles become motionless (Fig. 7 C). The
whole monolayer is not immobile, and ﬂuid domains can be
found, but for the most part the monolayer motion is
retarded. The reduction in mobility is not only seen in the
trajectories but in the diffusion coefﬁcient—which, for the
solid domain, is reduced to less than half of that with the
plain monolayer (Fig. 7 D).
CONCLUSIONS
Ab peptide-membrane interactions have implications not
only for the production of Ab but also for the onset of cell
death. Our FRET studies on cell membrane model systems
suggest that Ab inserts itself into the bilayers. FRET is
observed in GUVs, indicating incorporation of the peptide in
the membrane. Upon excitation with blue light and imaging
the green channel (which is the Ab ﬂuorophore color), we
see that there is peptide around the GUV. However, at the
location of the GUV, there is no green ﬂuorescence, which
suggests that all the ﬂuorescence in this location is trans-
ferred to the TR lipids in the membrane. Since the Ab pep-
tides are hydrophobic, the peptides are believed to insert into
the carbon chain part of the phospholipids. This assumption
is supported by the AFM studies that demonstrate that the
peptides are incorporated into the lipid monolayer. Using
visible FRET in nested vesicles inside the GUVs, the Ab
aggregates were also found to move through the giant vesicle
membrane to its interior. Nested vesicles were observed to
display rapid motion, suggesting that they are not invagina-
tions of the bigger vesicles, but freely moving entities. The
nested vesicles displayed substantial FRET, indicating that
FITC-Ab can rapidly cross the GUV bilayer and incorporate
in the bilayer of nested vesicles (Fig. 2 D). This is a very
important observation as these peptide aggregates are re-
sponsible for cell death. The SPT experiments further con-
ﬁrm that the Abs are incorporated into the lipid monolayer as
revealed though a large reduction in monolayer ﬂuidity. Our
results are consistent with previous reports demonstrating
that the incorporation of Ab peptides into a lipid bilayer
decreases the membrane ﬂuidity (52). We see a formation of
solid domains when the peptide is introduced; the mobility in
these domains is very low, but there are still ﬂuid regions,
and in these regions the lipid monolayer exhibits the same
mobility as before the introduction of the peptides. Our TEM
and AFM results demonstrate the degeneration of mature Ab
ﬁbrils into soluble oligomers. The ability of Ab to insert into
the plasma membrane has many implications for both cell
FIGURE 7 Lipid diffusion experiments investigating
ﬂuidity of membrane. (A) Trajectories of tracked lipids in
a monolayer without peptide. (B) Diffusion coefﬁcient
histogram for the lipid monolayer, the y axis representing
the fractional distribution with the total number total
number of tracked vesicles being 123. (C) Trajectories of
tracked lipids in a monolayer with incorporated peptide.
(D) Diffusion coefﬁcient histogram for lipid monolayer
with incorporated peptide, the y axis representing the
fractional distribution with the total number of tracked
vesicles being 144.
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survival and cell-driven ﬁbril degeneration. Although we
have examined Ab-lipid interactions in different model
systems, we have not taken into account the effect of other
cellular proteins residing in the membranes of cells. Integral
membrane proteins will also have an effect on Ab-mem-
brane interactions whether as competitors for Ab binding or
as modulators of bilayer properties. Our results demonstrate
the consequences of Ab-lipid interactions, which may play a
role not only in the normal cellular processing and turnover
of Ab but in the progression of disease processes in
Alzheimer’s disease.
This work was supported by the Center on Polymer Interfaces and
Macromolecular Assemblies, a National Science Foundation sponsored
partnership.
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